Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

January 30, 2024

https://www.prnewswire.com/news-releases/chemomab-therapeutics-announces-new-publication-reinforcing-the-clinical-potential-of-its-ccl24-neutralizing-antibody-cm-101-in-primary-sclerosing-cholangitis-302047524.html

—Proteomic Analysis of Human Samples Highlights the Unique Role of CCL24 in Activating Key PSC-related Disease Mechanisms Involving Immune Cell Trafficking and HSC Activation, Further Confirming the Potential of Chemomab’s CCL24-Neutralizing Antibody CM-101 as a Promising Therapy for PSC—

Read more at prnewswire.com

Related news for (CMMB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.